Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/73250
Title: 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout
Authors: Jose Paulo P. Lorenzo
Ma Hanna Monica Z. Sollano
Evelyn O. Salido
Julie Li-Yu
Sandra A. Tankeh-Torres
Ida Ayu Ratih Wulansari Manuaba
Md Mujibur Rahman
Binoy J. Paul
Mo Yin Mok
Monika De Silva
Prasanta Padhan
Ai Lee Lim
Melvin Marcial
Jennifer Jeanne Vicera
Syed Atiqul Haq
Sami Salman
Chiranthi K. Liyanage
Helen I. Keen
Cheng Yew Kuang
James Cheng Chung Wei
Rakhma Yanti Hellmi
Charlie E. Chan
Worawit Louthrenoo
Authors: Jose Paulo P. Lorenzo
Ma Hanna Monica Z. Sollano
Evelyn O. Salido
Julie Li-Yu
Sandra A. Tankeh-Torres
Ida Ayu Ratih Wulansari Manuaba
Md Mujibur Rahman
Binoy J. Paul
Mo Yin Mok
Monika De Silva
Prasanta Padhan
Ai Lee Lim
Melvin Marcial
Jennifer Jeanne Vicera
Syed Atiqul Haq
Sami Salman
Chiranthi K. Liyanage
Helen I. Keen
Cheng Yew Kuang
James Cheng Chung Wei
Rakhma Yanti Hellmi
Charlie E. Chan
Worawit Louthrenoo
Keywords: Medicine
Issue Date: 1-Jan-2022
Abstract: Background: Gout is the most prevalent inflammatory arthritis in the Asia-Pacific region and worldwide. This clinical practice guideline (CPG) aims to provide recommendations based on systematically obtained evidence and values and preferences tailored to the unique needs of patients with gout and hyperuricemia in Asia, Australasia, and the Middle East. The target users of these guidelines are general practitioners and specialists, including rheumatologists, in these regions. Methods: Relevant clinical questions were formulated by the Steering Committee. Systematic reviews of evidence were done, and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation methodology. A multi-sectoral consensus panel formulated the final recommendations. Results: The Asia-Pacific League of Associations for Rheumatology Task Force developed this CPG for treatment of gout with 3 overarching principles and 22 recommendation statements that covered the treatment of asymptomatic hyperuricemia (2 statements), treatment of acute gout (4 statements), prophylaxis against gout flare when initiating urate-lowering therapy (3 statements), urate-lowering therapy (3 statements), treatment of chronic tophaceous gout (2 statements), treatment of complicated gout and non-responders (2 statements), treatment of gout with moderate to severe renal impairment (1 statement), and non-pharmacologic interventions (5 statements). Conclusion: Recommendations for clinically relevant scenarios in the management of gout were formulated to guide physicians in administering individualized care.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85121450757&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/73250
ISSN: 1756185X
17561841
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.